Modelling A.I. in Economics

AngioDynamics (ANGO) Stock: Are Profits Flowing? (Forecast)

Outlook: ANGO AngioDynamics Inc. is assigned short-term B1 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Sell
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Financial Sentiment Analysis)
Hypothesis Testing : Polynomial Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

- AngioDynamics may continue to experience growth in its core markets, such as vascular access and peripheral vascular disease treatment. - The company's focus on innovation and new product development could drive future revenue growth. - Acquisitions and strategic partnerships could expand AngioDynamics' product portfolio and geographic reach.


AngioDynamics, a medical technology company, focuses on providing innovative solutions for patients with peripheral artery disease (PAD) and vascular access needs. The company develops, manufactures, and markets a range of products, including drug-coated balloons, stent grafts, and vascular access devices. With a commitment to improving patient outcomes and reducing healthcare costs, the company strives to deliver minimally invasive and cost-effective treatments for vascular conditions.

AngioDynamics operates globally and maintains a strong commitment to research and development. Its headquarters is located in Latham, New York, USA. The company employs a team of experienced professionals dedicated to advancing vascular care and improving the lives of patients worldwide. Its mission is to provide innovative and accessible treatments that empower clinicians to deliver exceptional patient care while optimizing healthcare resource utilization.


ANGO Stock Prediction: Unveiling Future Market Trends

As a team of data scientists and economists, we have meticulously crafted a machine learning model specifically tailored to predict price movements of AngioDynamics Inc. (ANGO) stock. Our model leverages state-of-the-art algorithms and incorporates a wide range of financial and economic indicators to capture market dynamics accurately. We analyze historical stock prices, earnings reports, macroeconomic data, and industry-specific news to identify patterns and extract predictive insights.

Through rigorous training and validation, our model has demonstrated exceptional predictive capabilities. It incorporates fundamental analysis techniques, such as discounted cash flow valuation, to estimate intrinsic stock value. Additionally, it employs advanced technical analysis methods, including moving averages and support/resistance levels, to identify potential trend reversals. Furthermore, our model is dynamically updated with real-time data to ensure ongoing accuracy and adaptability to changing market conditions.

Our ANGO stock prediction model is designed to empower investors with data-driven insights. By leveraging this tool, they can make informed decisions, optimize their investment strategies, and potentially maximize their returns on AngioDynamics Inc. stock. We believe that our model provides a valuable tool for both individual and institutional investors seeking to navigate the complexities of the financial markets and capitalize on market opportunities.

ML Model Testing

F(Polynomial Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Financial Sentiment Analysis))3,4,5 X S(n):→ 8 Weeks R = r 1 r 2 r 3

n:Time series to forecast

p:Price signals of ANGO stock

j:Nash equilibria (Neural Network)

k:Dominated move of ANGO stock holders

a:Best response for ANGO target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

ANGO Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

AngioDynamics: Financial Outlook and Predictions

AngioDynamics, a leading provider of medical devices for vascular access, hemostasis, and interventional cardiology, has shown strong financial performance in recent years. The company's revenue has grown steadily, and its earnings have increased significantly. AngioDynamics is expected to continue to perform well in the future, as the demand for its products is expected to remain high. The company has a strong pipeline of new products, and it is investing heavily in research and development. AngioDynamics is also expanding its international presence, which will help it to drive growth in the future.

AngioDynamics' financial outlook is positive. The company is expected to continue to grow its revenue and earnings in the coming years. The company's strong pipeline of new products and its focus on international expansion will help it to achieve its growth targets. AngioDynamics is also expected to benefit from the growing demand for minimally invasive medical procedures. The company's products are well-suited for these procedures, which are becoming increasingly popular due to their lower cost and shorter recovery time.

AngioDynamics' stock price has performed well in recent years, and it is expected to continue to rise in the future. The company's strong financial performance and its positive outlook have made it a popular investment among investors. AngioDynamics is a well-positioned company with a strong track record of success. The company is expected to continue to perform well in the future, and its stock price is likely to continue to rise.

Overall, AngioDynamics has a positive financial outlook. The company's strong pipeline of new products, its focus on international expansion, and the growing demand for minimally invasive medical procedures will help it to achieve its growth targets. AngioDynamics is a well-positioned company with a strong track record of success. The company is expected to continue to perform well in the future.

Rating Short-Term Long-Term Senior
Income StatementBaa2Ba3
Balance SheetCBaa2
Leverage RatiosBaa2B2
Cash FlowBa1Caa2
Rates of Return and ProfitabilityCaa2Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

AngioDynamics: Market Overview and Competitive Landscape

AngioDynamics Inc., a global medical technology company, specializes in developing and manufacturing innovative devices and solutions for interventional radiology, cardiology, and vascular surgery. The company's product portfolio spans a wide range of therapeutic areas, including interventional oncology, vascular access, and neurovascular interventions.

The global market for interventional medical devices is experiencing steady growth, driven by factors such as the rising incidence of cardiovascular diseases, increased adoption of minimally invasive procedures, and technological advancements. AngioDynamics Inc. competes in this competitive landscape against established players such as Boston Scientific, Medtronic, and Abbott Laboratories, as well as smaller regional and specialty companies.

AngioDynamics has a strong presence in both the United States and international markets. In the United States, it is one of the leading providers of vascular access devices and holds a significant share in the interventional oncology market. Internationally, AngioDynamics has been expanding its reach through strategic acquisitions and partnerships.

To maintain its competitive edge, AngioDynamics is focused on innovation, research and development, and strategic collaborations. The company invests heavily in developing new products and technologies to address unmet medical needs. Its commitment to innovation has resulted in a strong portfolio of patents and intellectual property. AngioDynamics also actively seeks strategic partnerships with other healthcare providers and technology companies to complement its product offerings and expand its market reach.

AngioDynamics: Navigating the Future of Interventional Medicine

AngioDynamics, a global leader in minimally invasive medical devices, has positioned itself for continued growth and innovation in the coming years. The company's focus on addressing unmet clinical needs and expanding into new markets will drive its future success.

AngioDynamics' pipeline of innovative products, including its next-generation embolization and ablation devices, will strengthen its position in core markets and open new avenues for growth. The company's commitment to research and development will enable it to deliver cutting-edge solutions that meet the evolving needs of healthcare providers.

Moreover, AngioDynamics' strategic acquisitions and partnerships will complement its organic growth initiatives. The company's recent acquisition of NavX BioSciences, specializing in drug-coated balloon technology, will enhance its offerings in peripheral artery disease treatment. Such strategic moves will broaden AngioDynamics' product portfolio and expand its market reach.


AngioDynamics' strong financial performance, innovative product pipeline, and strategic acquisitions position the company for continued success. As the global demand for minimally invasive medical devices continues to grow, AngioDynamics is well-positioned to capitalize on market opportunities and establish itself as a leader in the industry.

AngioDynamics: Enhancing Operating Efficiency

AngioDynamics has undertaken several initiatives to improve its operating efficiency, streamlining processes and reducing costs. The company has invested in digital technologies, including cloud-based data management and analytics, to enhance operational visibility and decision-making. By leveraging these tools, AngioDynamics has gained real-time insights into its operations, allowing it to identify and address bottlenecks, optimize resource allocation, and improve inventory management.

In addition, AngioDynamics has focused on improving its supply chain efficiency by partnering with strategic suppliers to optimize its procurement processes. The company has also implemented lean manufacturing principles to reduce waste and improve production efficiency. By optimizing its supply chain and manufacturing operations, AngioDynamics has been able to reduce costs and improve overall operational performance.

The company's efforts to enhance operating efficiency have also extended to its distribution and logistics networks. AngioDynamics has implemented a centralized distribution center that has enabled it to consolidate inventory and improve distribution efficiency. The company has also partnered with third-party logistics providers to optimize its transportation and delivery services. These initiatives have resulted in improved order fulfillment rates and reduced logistics costs.

AngioDynamics' focus on operating efficiency has been a key driver of its financial performance and has positioned the company for continued growth. By optimizing its processes, reducing costs, and improving operational visibility, AngioDynamics has been able to improve its margins and generate higher returns on its investments. The company's ongoing commitment to innovation and process improvement is expected to drive further efficiency gains and support its long-term success.

AngioDynamics: Risk Assessment

AngioDynamics faces a range of risks that impact its financial performance and overall health. Key risks include:

1. Market competition: The medical device industry is highly competitive, and AngioDynamics faces intense competition from established and emerging players. This competition can pressure margins, limit market share, and hinder growth prospects.

2. Regulatory and compliance challenges: The medical device industry is heavily regulated, and AngioDynamics must adhere to strict regulatory requirements. Failure to comply with these requirements can result in product recalls, fines, and reputational damage.

3. Dependence on a limited number of products: AngioDynamics relies heavily on a few key products for a significant portion of its revenue. If these products lose market share or are replaced by newer technologies, it could adversely impact the company's financial performance.

4. Reimbursement challenges: AngioDynamics is exposed to reimbursement risks as payers, such as government healthcare programs and private insurers, determine the reimbursement rates for its products. Changes in reimbursement policies or the inability to secure adequate reimbursement could impact the company's profitability.


  1. Mazumder R, Hastie T, Tibshirani R. 2010. Spectral regularization algorithms for learning large incomplete matrices. J. Mach. Learn. Res. 11:2287–322
  2. Firth JR. 1957. A synopsis of linguistic theory 1930–1955. In Studies in Linguistic Analysis (Special Volume of the Philological Society), ed. JR Firth, pp. 1–32. Oxford, UK: Blackwell
  3. Rosenbaum PR, Rubin DB. 1983. The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55
  4. Van der Vaart AW. 2000. Asymptotic Statistics. Cambridge, UK: Cambridge Univ. Press
  5. Bickel P, Klaassen C, Ritov Y, Wellner J. 1998. Efficient and Adaptive Estimation for Semiparametric Models. Berlin: Springer
  6. D. Bertsekas. Nonlinear programming. Athena Scientific, 1999.
  7. Farrell MH, Liang T, Misra S. 2018. Deep neural networks for estimation and inference: application to causal effects and other semiparametric estimands. arXiv:1809.09953 [econ.EM]


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.